Hepatitis C: molecular virology and antiviral targets.
Chronic hepatitis C is a leading cause of liver cirrhosis and hepatocellular carcinoma worldwide. Although current treatment options are limited, progress in understanding the molecular virology of hepatitis C has led to the identification of novel antiviral targets. Moreover, in vitro and in vivo model systems have been developed that allow systematic evaluation of new therapeutic strategies. This review details current concepts in molecular virology and emerging therapies for hepatitis C.
Moradpour
Darius
D
Department of Medicine II, University of Freiburg, Hugstetter Strasse 55, Germany. Darius.Moradpour@uni-freiburg.de
Brass
Volker
V
Gosert
Rainer
R
Wölk
Benno
B
Blum
Hubert E
HE
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D005814:Genes, Viral; D016174:Hepacivirus / Q000235:genetics* / Q000378:metabolism / Q000648:ultrastructure; D006526:Hepatitis C / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy* / Q000821:virology*; D006801:Humans; D008958:Models, Molecular; D011499:Protein Processing, Post-Translational; D020836:Protein Structure, Quaternary; D015678:Viral Structural Proteins / Q000737:chemistry / Q000378:metabolism
D000998:Antiviral Agents; D015678:Viral Structural Proteins